Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Sorrels

Internal Medicine Cushing, OK Medical Doctor

NPI 1023085636 CMS profile 91566

1030 E Cherry St, Cushing, OK 74023

Open in the dashboard

General payments

$3,135

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Sorrels of Cushing, OK is reported in the CMS Open Payments database as having received $3,135 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $446 26
2024 General $609 21
2023 General $378 22
2022 General $570 30
2021 General $124 1
2020 General $169 5
2019 General $839 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Sorrels
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Sorrels were reported at $446. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Sorrels Internal Medicine median Middle half National median
2019 $839 $159 $48–$570 $163
2020 $169 $119 $33–$402 $114
2021 $124 $135 $37–$521 $132
2022 $570 $141 $42–$496 $149
2023 $378 $149 $45–$519 $160
2024 $609 $154 $47–$537 $164
2025 $446 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $744 36 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $634 15 payments
  3. AstraZeneca Pharmaceuticals LP $592 21 payments
  4. Novo Nordisk Inc $329 16 payments
  5. AbbVie, Inc. $220 12 payments
  6. Supernus Pharmaceuticals, Inc. $87 5 payments
  7. Janssen Pharmaceuticals, Inc $69 5 payments
  8. Exact Sciences Corporation $69 3 payments
  9. Pfizer Inc. $64 4 payments
  10. Teva Pharmaceuticals USA, Inc. $55 3 payments
  11. Other $272 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,129 133 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $621 14 payments
  2. MOUNJARO $397 19 payments
  3. FARXIGA $360 13 payments
  4. TRULICITY $340 19 payments
  5. AIRSUPRA $207 3 payments
  6. JARDIANCE Diabetes $183 10 payments
  7. BREZTRI $159 6 payments
  8. Wegovy $149 4 payments
  9. Ozempic $148 10 payments
  10. ZEPBOUND $134 9 payments
  11. Other $1,129 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 212 drugs

Part D claims

15,046

Median for Internal Medicine: 777

Drug cost

$1,140,092

Median for Internal Medicine: $73,373

Branded share of claims

21.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 139 $150,651
Ozempic Semaglutide Brand 113 $141,197
Eliquis Apixaban Brand 214 $130,588
Austedo Deutetrabenazine Brand 12 $89,386
Farxiga Dapagliflozin Propanediol Brand 90 $49,922
Xarelto Rivaroxaban Brand 64 $47,104
Vraylar Cariprazine Hcl Brand 21 $29,209
Jardiance Empagliflozin Brand 27 $29,131
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 13 $21,636
Rybelsus Semaglutide Brand 18 $18,552

The 10 drugs with the highest cost, of 212 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$2,430

Of which drugs: $80

Medicare patients

101

Average age 75

Services billed

1,097

57 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 44%
Ischemic heart disease 38%
Depression 30%
COPD 28%
Heart failure 24%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 520 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $157
$157 — —
Wegovy
  • Novo Nordisk Inc $149
$149 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $65
$65 20 —
YUPELRI
  • Mylan Specialty L.P. $40
$40 — —
VRAYLAR
  • AbbVie, Inc. $34
$34 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record